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Rational application of fructose-1,6-diphosphate:
From the perspective of pharmacokinetics
Fructose-1,6-diphosphate (FDP), a glycolytic metabolite, 
has been reported to protect susceptible organs during hy-
poxia or ischemia. However, there is paucity of human data 
on its pharmacokinetics a er being exogenously adminis-
tered. In the current study, the preliminary pharmacoki-
netics of FDP given orally to humans was investigated, and 
no typical peak was observed in the serum drug-time 
curve. Then, the pharmacokinetic studies were performed 
following multiple doses of FDP in rats, and the Caco-2 
monolayer model was used to study the absorption of FDP 
in vitro. The results suggested that plasma FDP concentra-
tion was signiﬁ cantly increased a er oral multiple doses of 
180 mg kg–1 but not 90 mg kg–1 of FDP, and FDP was partly 
depleted during the absorption, which was supposed to be 
consumed by the intestinal epithelium cells. Thus, we con-
clude that a high dose of FDP should be orally adminis-
tered in order to get an eﬀ ective plasma level.
Keywords: fructose-1,6-diphosphate, ischemia, hypoxia, 
pharmacokinetics
Fructose-1,6-diphosphate (FDP) is an endogenous intermediate metabolite of glucose. 
Most of glucose and fructose is converted to FDP when entering a cell. It has been increas-
ingly recognized that FDP can protect ischemic or hypoxic tissue a er acute ischemia, al-
though the mechanisms have not been fully clariﬁ ed yet.
Previous studies suggested that exogenous FDP could augment the anaerobic carbo-
hydrate utilization and improve the cellular energy metabolism in ischemic and hypoper-
fused tissues. Hypoxia forces ischemic tissue to anaerobic glycolysis for energy, which 
yields two molecules of ATP per glucose in contrast to 36 molecules of ATP generated dur-
ing oxidative phosphorylation (1). Addition of exogenous FDP can produce two more mole-
cules of ATP in an uncompensated anaerobic environment and hence facilitate the recov-
ery of ischemia tissue. FDP breaks down into glyceraldehyde-3-phosphate and 
dihydroxyacetone phosphate, which will further break down into two molecules of pyru-
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Other mechanisms include inhibition of the generation of oxygen free radicals by 
neutrophils, stabilization of cell membranes, and maintainance of the correct xanthine 
dehydrogenase/oxidase ratio by preventing the depletion of phosphorylated compounds 
in ischemic tissues (2, 3).
In myocardial infarction patients, FDP can improve the hemodynamic parameters, 
a enuate ECG proven ischemic injury and arrhythmia, prevent ATP and creatine phos-
phate depletion from ischemic myocardium, reduce infarct size, and increase survival rate 
(4). Exogenously administered FDP has also been proven beneﬁ cial for a variety of other 
ischemic organs, such as liver, kidney, bowel and even brain as a consequence of its ability 
to penetrate to the blood brain barrier (5–7). In China, FDP has been approved and mar-
keted as a commercial drug.
The pharmacokinetic study of FDP is demanding due to endogenous interferences. A 
very high dose is needed to achieve a substantial increase of FDP plasma concentration 
and generate a comprehensive plasma concentration-time course. Doses used in the ani-
mal study varied from 350 to 700 mg kg–1 when given by gavage or intraperitoneally (8, 9).
According to Xu and Stringer (10), a complete time course of the levels in blood and 
brain was observed a er intraperitoneal administration of a single 500 mg kg–1 dose of FDP 
to adult male Sprague-Dawley rats. The recommended dose for patients is 1 g, tid, i.e., 42.8 
mg kg–1 per day. In this study, we ﬁ rst investigated whether the currently recommended 
total daily dose of FDP (3 g, 42.8 mg kg–1) was adequate to increase the plasma level of FDP 
in human volunteers. Then, a study was conducted to investigate the pharmacokinetic 
proﬁ le of FDP in rats.
EXPERIMENTAL
Materials
Fructose diphosphate sodium tablets (1 g of FDP per tablet) and the corresponding 
placebo tablets were manufactured by Ling Kang Pharmaceutical Co., Ltd. (China). The FDP 
standard (C6H11Na3O12P2 · 8H2O, Mr 550.17, purity 73.4 %) was purchased from the National 
Institute for the Control of Pharmaceutical and Biological Products (China). Blank plasma 
was supplied by the West China Hospital, Sichuan University (Chengdu, Sichuan, China) 
and was covered by institutional approval. The special solid complex enzyme reagent, a 
Fig. 1. The role of fructose-1,6-diphosphate (FDP) in energy metabolism. A – glyceraldehyde-3-phos-
phate, B – dihydroxyacetone phosphate, C – phosphoenolpyruvate, D – pyruvate.
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mixture of aldolase (ALD), triosephosphate isomerase (TIM) and glycerol-3-phosphate de-
hydrogenase (GDH) in a certain proportion, was purchased from Chung Yi Long Run Co., 
Ltd. (China), and nicotinamide adenine dinucleotide (NADH) from Sinopharm Chemical 
Reagent Co., Ltd. (China). The deionized water used in this study was puriﬁ ed using a Mil-
lipore AFS-10 water puriﬁ cation system (Millipore, USA). All other chemicals were of ana-
lytical grade and were purchased from local chemical suppliers.
Caco-2 cells were supplied by the Type Culture Collection of the Chinese Academy of 
Sciences (Shanghai, China). Dulbecco’s modiﬁ ed eagle’s medium (DMEM) was purchased 
from Gibco Laboratories (Life Technologies Inc., USA), HyClone™ fetal calf serum from 
Thermo Fisher Scientiﬁ c (USA), and trypsin-EDTA solution (0.25 %) from Amresco (USA). 
Hank’s balanced salts solution (HBSS) was purchased from Solarbio (Beĳ ing Solarbio Sci-
ence &Technology Co., Ltd., China). Polycarbonate ﬁ lter membranes (Transwell inserts) 
were obtained from Corning Costar Corp. (Corning, USA).
Assay development
Analytical methods and principles. – FDP concentration was determined by monitoring 
the absorbance of NADH reduced by a special solid complex enzyme (ALD, TIM and 
GDH) reagent. Aldolase (ALD) cleaves FDP into dihydroxyacetone phosphate (DAP) and 
D-glyceraldehyde 3-phosphate (GAP). Then DAP and GAP are interconverted by the en-
zyme triosephosphate isomerase (TIM). In the presence of the above reaction products, 
glycerol-3-phosphate dehydrogenase (GDH) catalyzes the reduction of DAP by NADH (10).
Brieﬂ y, 30 mg of the special solid complex enzyme and 3 mg of NADH were dissolved 
in 10 mL of tetraethylammonium buﬀ er (TEA, 0.4 mol L–1, pH 7.6 with 40 mmol L–1 of 
EDTA) before analysis, which was called »mingle enzyme«. For FDP measurements, 2 mL 
of TEA buﬀ er and 1 mL of the »mingle enzyme« were added into a 4-mL cuve e, followed 
by mixing for 5 min at room temperature. The absorbance was then repeatedly measured 
each minute for 10 min at 340 nm. The concentration of FDP in the sample was propor-
tional to the change of absorbance intensity.
FDP standard (54.51 mg) was accurately weighed and dissolved in 10 mL of deionized 
water to prepare the stock solution. Working solutions of FDP with concentrations of 12.5, 
25, 50, 100, 200, 400, 500 µg mL–1 were prepared by appropriately diluting the stock solution 
using deionized water (for FDP analysis in plasma) or Hank’s Balanced Salt Solution (HBSS) 
(for FDP analysis in the transport medium). The stock solution and working solutions were 
stored at 4 °C and tested to be stable for at least 1 month. Calibration standards for FDP 
analysis in plasma were prepared by spiking 50 µL of working solutions into 500 µL of blank 
plasma (for FDP analysis in plasma) or HBSS (for FDP analysis in the transport medium). 
Three levels of QC samples were chosen as low, medium and high calibration standard 
concentrations, i.e., 25, 100 and 400 µg mL–1. The QC samples were stored at –20 °C with the 
sample to be analyzed. Blank sample and FDP standard samples were run in parallel with 
every assay. The environmental temperature for detecting FDP was set at 25 °C.
Method validation
Method validation was done by evaluating linearity, intra-day and inter-day precision 
as well as accuracy and recovery. The QC samples were prepared by spiking the three 
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levels of QC working solutions (25, 100 and 400 µg mL–1) into blank plasma. Accuracy and 
precision of the method were assessed by determining QC samples using ﬁ ve replicate 
preparations on 3 separate days. Extraction recoveries at low, medium and high concentra-
tions were evaluated by comparing the change of absorbance intensity obtained from the 
QC samples with that from the samples prepared by spiking working solutions into de-
ionized water.
Pharmacokinetic studies
Study participants. – Preliminary pharmacokinetic studies in humans were performed 
in two healthy male Chinese volunteers (21 and 22 years old) by administering the doses 
of 3 g FDP (~ 43 mg kg–1). Two healthy male Chinese volunteers (body mass 70.3 and 69.5 
kg) were selected a er clinical assessment of their health status to ensure that they had no 
history or current evidence of any gastrointestinal, hepatic, renal, or hematologic abnor-
mality, acute infection, chronic disease, or allergy to any drugs. Both of them were non-
drinkers and nonsmokers, and did not use drugs for 2 weeks before the study. The proto-
col was approved by the Ethics Commi ee of the Xĳ ing Hospital, Fourth Military Medical 
University of Chinese People’s Liberation Army. Both provided wri en informed consent.
Food intake may modify the pharmacokinetics of a drug by altering the bioavailabil-
ity of the drug during absorption (11). Caﬀ einated and alcoholic beverages may also aﬀ ect 
the metabolism of certain drugs (12). In this study, volunteers were fasted for at least 12 
hours. Food and beverage were prohibited for 4 hours post dosing. Consumption of bever-
ages containing caﬀ eine or alcohol was not allowed during the study.
Study design and drug administration. – The st u dy was conducted with a single blind and 
parallel design. The ﬁ rst day, two volunteers received a single 3-g oral dose of placebo and 
4-mL blood sample was drawn into a heparinized tube before and at 0.25, 0.5, 0.75, 1, 1.25, 
1.5, 2, 2.5, 3, 4, 5, 6 and 8 h post dose to analyze the baseline levels of FDP in plasma. The 
next day, they received the same oral dose of FDP and the corresponding blood samples 
were collected as aforementioned. Blood samples were centrifuged at 4000 rpm for 5 min. 
The plasma sample was separated and stored at –20 °C until analysis.
Sample preparation. – Fi y µL of deionized water was added to 0.5 mL of plasma sample 
and mixed. Then, 50 µL perchloric acid (30 %, m/m) was added and mixed for 5 min. A er 
centrifugation at 12000 rpm for 5 min at 4 °C, the supernatant was collected in another tube 
and 20 µL of sodium carbonate solution (2.5 mol L–1) was added in order to adjust the pH 
to 3.5. Then, the samples underwent another mixing and centrifugation at 12000 rpm for 5 
min at 4 °C. The supernatant was collected and used for determination of FDP levels as 
described above.
Pharmacokinetic studies of FDP
The pharmacokinetic study of FDP following oral administration was carried out us-
ing adult male Sprague-Dawley rats (180–230 g) obtained from the Laboratory Animal 
Center of West China University of Medical Science (Sichuan, China). All the animals were 
housed individually with free access to food and water under standard conditions (con-
trolled temperature and humidity with 12-h light:dark cycles). Animal experiments in this 
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study were conducted in accordance with the Guidelines for the Care and Use of Labora-
tory Animals and were approved by the Institutional Animal Care and Use Commi ee of 
Sichuan University.
Ten rats were randomly divided into low dose (90 mg kg–1) or high dose (180 mg kg–1) 
groups. FDP was dissolved in phosphate buﬀ ered saline (pH = 7) to a concentration of 10 
mg mL–1. The rats received FDP three times a day for 7 consecutive days. Before dosing, 
0.4 mL of blood was drawn a er 12 h fasting as a control sample to measure the baseline. 
On the morning of the eighth day, 0.4-mL blood samples were drawn from the tail vein 
before and at 10, 20, 30 and 45 min and 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12.0 h a er the dose. 
Samples were centrifuged at 4000 rpm for 5 minutes and plasma was separated and stored 
at –20 °C until analysis.
Study of biliary excretion of FDP in rats
Ten adult male rats were randomly divided into two groups (test and control). The rats 
received either FDP (180 mg kg–1, three times a day) or equal amount of phosphate buﬀ ered 
saline by gavage for 7 consecutive days. On the eighth day, a er the last dose, bile samples 
were taken a er 2, 4, 6, 8 and 12 h from the bile duct cannulation. All bile samples were 
stored at –20 °C for later analyses.
Absorption of FDP on monolayers of human intestinal epithelial (Caco-2) cells
Cell culture. – Caco-2 cells were cultured in high glucose Dulbecco’s modiﬁ ed Eagle’s 
medium (DMEM) supplemented with 10 % fetal bovine serum. Cells were cultured in a 
humidiﬁ ed atmosphere of 5 % CO2 at 37 °C. A er reaching 80 % conﬂ uence, the Caco-2 
cells were harvested using 0.25 % trypsin-EDTA. For transport experiments, the cells were 
seeded onto polycarbonate ﬁ lter membranes in 6-well plates at a density of 1.0 × 105 cells 
cm–2 and grown for 21 days before the experiments. The protocols for cell culture in the 
polycarbonate ﬁ lter membranes were similar to those described previously (13).
Cytotoxicity of FDP. – The cytotoxicity of FDP to Caco-2 cells was examined using a 
sulforhodamine B (SRB) approach. Brieﬂ y, Caco-2 cells were seeded onto 96-well plates (0.1 
mL per well, containing 500 cells per well) and incubated for 48 h at 37 °C. Then, cells were 
incubated with various concentrations of FDP (0, 10, 40, 80, 100, 120, 140, 160, 200, 300, 400 
µg mL–1) for 3 h. A erwards, the cells were ﬁ xed using methanol and cellular proteins 
were dyed with 0.1 mL 0.4 % (m/V) SRB in 1 % acetic acid. Cell-bound dye was dissolved 
with 0.1 mL 10 mmol L–1 Tris buﬀ er (pH = 10.5) and the absorbance of each concentration 
was measured at 492 nm. No FDP treated group was set as control. Cell viability was pro-
portional to the absorbance.
Transport experiments. – The integrity and transportation ability of the Caco-2 cell 
monolayer were examined by measuring the transepithelial electrical resistance (TEER) 
with an epithelial volt-ohm meter and detecting the activity of alkaline phosphates. Only 
the cell monolayer with a TEER of above 500 ohm cm–2 was used for transport assays. Dif-
ferentiation of Caco-2 cells was checked on the 3rd and 14th day by determining the activ-
ity of alkaline phosphates.
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A er washing the Caco-2 cell monolayer twice with HBSS medium (pH = 7.4) pre-
warmed to 37 °C, transport experiments were conducted by adding the FDP solutions to 
the apical chamber (AP, 1.5 mL) while 2.5 mL of blank HBSS medium was added to the 
basolateral (BL) chamber. A er 0, 15, 30, 45, 60, 75, 90, 105, 120, 150 and 180 min incubation 
at 37 °C, a 0.1-mL sample was collected from the BL side to study the drug transport of the 
apical to basolateral (AP to BL) chamber and meanwhile an equal volume of blank HBSS 
was replenished to BL. Also, 0.1-mL samples from the AP side were collected at the begin-
ning and at the end of the experiment. Three loading concentrations of 100, 200 and 400 µg 
mL–1 were used in triplicate. All samples were preserved at –20 °C until analysis.
FDP released by Caco-2 cells. – Caco-2 cells were cultured in high glucose Dulbecco’s 
modiﬁ ed Eagle’s medium (DMEM) for 21 days, followed by replacing it with ﬂ esh medium 
and incubating for another 48 h (14). The medium at the end of the 48-h incubation was 
collected to determine the FDP concentration compared to that in fresh medium. All sam-
ples were preserved at –20 °C until analysis.
Data analysis
The cumulative mass (µg) of FDP in the basolateral (BL) chamber at time i was calcu-
lated using the following formula:
 QrBi = 0.1 ´ [gr1 + gr2 + ... + gr(i–1)] + 2.5 ´ gri (1)
where QrBi (µg) is the cumulative amount of FDP in BL chamber, gr1 is the FDP level (µg 
mL–1) of the sample in BL chamber from the ﬁ rst time point, gri is the level of the sample 
at time i in BL chamber, and 2.5 refers to the volume of BL chamber (2.5 mL).
Usually, drugs that are well absorbed in the intestine have permeability coeﬃ  cients 
> 1 × 10−6 cm s–1, and those which are hardly absorbed have permeability coeﬃ  cients 
≤ 1 × 10−7 cm s–1. The apparent permeability coeﬃ  cient (Papp), the coeﬃ  cient that reﬂ ects the 
absorption of a drug, was calculated based on the following equation:







where dQ/dt (µg s–1) is the cumulative transport rate of the compound on the receiving 
side, A is the surface area of the cell monolayer (cm2), and g0 is the initial concentration in 
the donor compartment (µg mL–1).
The recovery and absorption ratio of the transport experiment was calculated as:
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where gAf, gBf and gA0 refer to the ﬁ nal concentration of FDP in the AP chamber, BL cham-
ber, and initial concentration of FDP in AP chamber respectively, and VA and VB are the 
volume of AP and BL chambers.
Statistical analysis
Pharmacokinetic parameters were determined using the DAS version 3.1.6. gmax and 
tmax were determined using visual inspection of the FDP plasma concentration-time ﬂ ot. 
All results were expressed as mean ± SEM. The time course for FDP in plasma was ana-
lyzed with a one-way ANOVA comparing it to control levels as a function of time. Other 
comparisons were done using Student’s test. A p < 0.05 was considered to indicate a statis-
tically signiﬁ cant diﬀ erence.
RESULTS AND DISCUSSION
The intra-day precision of the assay was 8.8, 5.8 and 5.6 % and the inter-day precision 
are 9.7, 7.3 and 6.5 % for the low, medium and high concentration of FDP, respecting. The 
accuracies were 93.2, 96.2 and 91.8 % for the low, medium and high concentration of FDP, 
respectively. A good linear relationship was obtained in the range of 12.5–500 µg mL–1 in 
plasma and HBSS. The lower limit of quantiﬁ cation (LLOQ) was 12.5 µg mL–1. The mean 
extraction recovery was 91.8 ± 7.81, 96.2 ± 7.8 and 93.2 ± 2.5 % for the low, medium and high 
concentration of FDP, respectively.
Pharmacokinetics of FDP in human plasma
The FDP plasma concentration-time courses of the volunteers following oral admin-
istration of 3 g FDP or placebo are shown in Figs. 2a and 2b. Each point represents the 
concentration of FDP at the corresponding time. The concentration of FDP at baseline 
level varied from 58.61 to 110.64 µg mL–1 and 34.14 to 116.26 µg mL–1 for subjects A and B, 
respectively, which indicated physiological ﬂ uctuations. The peak concentration (gmax) and 
the time to achieve it (tmax) in volunteer A were 113.34 µg mL–1 and 3 h, and that for volun-
teer B were 119.83 µg mL–1 and 1.5 h.
No signiﬁ cant diﬀ erence in FDP plasma concentration was observed at 8 hours post 
dose of FDP tablets and placebo (89.10 ± 3.15 vs. 82.58 ± 3.72 µg mL–1 for subject A, while 
83.47 ± 4.39 vs. 84.42 ± 5.39 µg mL–1 for subject B). The results demonstrated that FDP failed 
to rise in plasma of humans at a dose of 3 g compared to an equivalent dose of placebo, 
indicating that the currently recommended dose of FDP from tablets may be inadequate 
to achieve clinically eﬀ ective concentrations.
Plasma pharmacokinetics and biliary excretion of FDP in rats
The FDP plasma concentration in rats following administration of FDP at a dose of 90 
mg kg–1 (every 8 hours for seven consecutive days) was substantially increased compared 
to the placebo group, although the increase did not reach a statistically signiﬁ cant level 
(Fig. 2c). gmax and tmax were 118.58 µg mL–1 and 45 min, respectively. Average FDP plasma 
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Fig. 2. Level of FDP in plasma of: a) volunteer A and b) volunteer B a er administration of 3 g of FDP 
and placebo. Kinetics of FDP a er gavage administration of c) 90 mg kg–1 and d) 180 mg kg–1 of FDP 
for consecutive seven days in rats. Each point indicates average and standard deviation, n = 5. Sig-
niﬁ cant diﬀ erence compared to the control value: *p < 0.05, #p < 0.01.
concentration within 12 h following oral administration of FDP was 93.61 µg mL–1, while 
the average value in the control group was 84.09 µg mL–1.
The FDP plasma concentration in rats following oral administration of 180 mg kg–1 
FDP (every 8 hours for seven consecutive days) was increased signiﬁ cantly, especially dur-
ing the ﬁ rst 0.5–1.5 h post dose (Fig. 2d). The gmax and tmax were 182.85 µg mL–1 and 45 min, 
respectively. AUC (0-t), AUC(0-∞) and t1/2 were 1086.7 µg L h–1, 1975.0 µg L h–1 and 8.14 h, 
respectively. The mean FDP concentration within 12 h post dose was 113.28 µg mL–1, while 
average for the control group was 71.98 µg mL–1. However, in Xu and Stringer’s study (10), 
the peak plasma concentration was only about 35 µg mL–1 a er a single dose of 500 mg kg–1 
FDP by intraperitoneal injection in rats, which was much lower than that in the present 
study. The multiple-dose in this study may signiﬁ cantly increase the concentration of FDP 
compared to the single-dose due to drug accumulation in plasma.
In addition, a bimodal phenomenon on the concentration-time curve was observed. 
The second concentration peak of 115 µg mL–1 was observed at 7 h post dose (Fig. 2d), 
which is consistent with Xu and Stringer’s study (10). The results indicated that enterohe-
patic circulation may exist.
a)                                                                                   b)
c)                                                                                    d)
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Fig. 3. a) Caco-2 cell viability (%) at diﬀ erent concentrations of FDP (10, 40, 80, 100, 120, 140, 160, 200, 
300, and 400 µg mL–1) (mean ± SD, n = 5 for 10 µg mL–1, n = 6 for others). Time course of FDP transport 
in Caco-2 cell monolayers at the concentration of: b) 100 µg mL–1, c) 200 µg mL–1, d) 400 µg mL–1 (mean 
± SD, n = 3).














× 10–5 (cm s–1)
100 14.89 ± 1.318 26.66 ± 3.292 31.51 ± 10.78 21.01 ± 7.19 63.27 ± 7.214 2.397 ± 0.5928
200 44.18 ± 3.491 55.60 ± 6.700 127.31 ± 7.83 42.44 ± 2.61 72.58 ± 5.048 4.473 ± 0.7643
400 60.36 ± 6.262 154.51 ± 14.259 179.73 ± 16.01 29.96 ± 2.67 72.17 ± 4.318 2.137 ± 0.2991
g0 – Concentration of FDP in chamber AP at the beginning of  transport experiments; 
gB and gA – Concentration of FDP in chamber BL and chamber AP at the end of  transport experiments.
QrB3h – The cumulative amount of FDP in BL chamber a er transporting for 3 h.
Papp – The apparent permeability coeﬃ  cient. 
Mean ± SD of 3 independent transport experiments.
FDP was not detected in biliary samples from the both test group and control group. 
Other mechanisms may exist. Following the oral dose of 180 mg kg–1 FDP (every 8 hours 
for seven days).
a)                                                                                         b)
 c)                                                                                       d) 
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Permeability of FDP through Caco-2 cells
Cell viabilities of Caco-2 cells in the presence of FDP at concentrations from 10 to 400 
µg mL–1 were all above 90 %, which suggested and released FDP by rather low cytotoxic-
ity of FDP on Caco-2 cells within 3 h (Fig. 3a).
The amount of FDP in BL chamber increased with time at loading concentrations of 
100, 200 and 400 µg mL–1 in AP chamber (Figs. 3b, 3c, 3d). At the end of the experiment, the 
cumulative FDP in BL chamber was 45.53, 127.3, and 179.61 µg, respectively.
The mean Papp value of FDP at three concentrations is listed in Table I; FDP was found 
to be high permeable (Papp > 1 × 10−6 cm s–1). However, the recoveries of FDP were poor (63, 
68, and 78 % for 100, 200 and 400 µg mL–1 group respectively). The intracellular FDP con-
centration was determined at the end of the transport experiment and was found to be 
very low. The results suggested that FDP could be consumed by Caco-2 cells during the 
transport experiment. Such a possibility would partially explain low recovery.
Caco-2 cells were cultured for 21 days on polycarbonate ﬁ lter membranes (surface area 
4.52 cm2) and were continuously incubated for another 48 h to investigate the FDP release. 
The results showed that the level of FDP in the ﬁ nal medium in AP (apical chamber) and 
BL (basolateral chamber) were 175.35 ± 2.37 and 174.51 ± 5.79 µg mL–1, respectively. No FDP 
was detected in fresh medium, which implied that FDP may be released from Caco-2 cells. 
The release of endogenous FDP could explain the second peak in the concentration-time 
curve (Fig. 2d), although further investigation is necessary to verify the hypothesis.
CONCLUSIONS
The results indicate that the currently recommended dose of FDP may be inadequate 
to signiﬁ cantly increase the plasma level of FDP and that a higher dose is needed. The 
consumption of FDP by the intestinal epithelium cells could be a major barrier for FDP 
absorption. In order to achieve the desired clinical therapeutic eﬀ ect, a higher dosage may 
be utilized in clinical se ings for mitigating the ischemic injury of organs apart from the 
intestine itself.
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